Cited 23 time in
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nada, Hossam | - |
| dc.contributor.author | Choi, Yongseok | - |
| dc.contributor.author | Kim, Sungdo | - |
| dc.contributor.author | Kwon, Su Jeong | - |
| dc.contributor.author | Meanwell, Nicholas A. | - |
| dc.contributor.author | Lee, Kyeong | - |
| dc.date.accessioned | 2024-12-23T07:30:13Z | - |
| dc.date.available | 2024-12-23T07:30:13Z | - |
| dc.date.issued | 2024-12 | - |
| dc.identifier.issn | 2095-9907 | - |
| dc.identifier.issn | 2059-3635 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/56457 | - |
| dc.description.abstract | Protein-protein interactions (PPIs) are fundamental to cellular signaling and transduction which marks them as attractive therapeutic drug development targets. What were once considered to be undruggable targets have become increasingly feasible due to the progress that has been made over the last two decades and the rapid technological advances. This work explores the influence of technological innovations on PPI research and development. Additionally, the diverse strategies for discovering, modulating, and characterizing PPIs and their corresponding modulators are examined with the aim of presenting a streamlined pipeline for advancing PPI-targeted therapeutics. By showcasing carefully selected case studies in PPI modulator discovery and development, we aim to illustrate the efficacy of various strategies for identifying, optimizing, and overcoming challenges associated with PPI modulator design. The valuable lessons and insights gained from the identification, optimization, and approval of PPI modulators are discussed with the aim of demonstrating that PPI modulators have transitioned beyond early-stage drug discovery and now represent a prime opportunity with significant potential. The selected examples of PPI modulators encompass those developed for cancer, inflammation and immunomodulation, as well as antiviral applications. This perspective aims to establish a foundation for the effective targeting and modulation of PPIs using PPI modulators and pave the way for future drug development. | - |
| dc.format.extent | 32 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | SPRINGER NATURE | - |
| dc.title | New insights into protein-protein interaction modulators in drug discovery and therapeutic advance | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1038/s41392-024-02036-3 | - |
| dc.identifier.scopusid | 2-s2.0-85211121556 | - |
| dc.identifier.wosid | 001371825000003 | - |
| dc.identifier.bibliographicCitation | Signal Transduction and Targeted Therapy, v.9, no.1, pp 1 - 32 | - |
| dc.citation.title | Signal Transduction and Targeted Therapy | - |
| dc.citation.volume | 9 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 32 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Cell Biology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Cell Biology | - |
| dc.subject.keywordPlus | SMALL-MOLECULE INHIBITORS | - |
| dc.subject.keywordPlus | IMMUNODEFICIENCY-VIRUS TYPE-1 | - |
| dc.subject.keywordPlus | ALANINE SCANNING MUTAGENESIS | - |
| dc.subject.keywordPlus | ANTI-CD4 MONOCLONAL-ANTIBODY | - |
| dc.subject.keywordPlus | OVERCOMING HERG AFFINITY | - |
| dc.subject.keywordPlus | STRUCTURE-BASED DESIGN | - |
| dc.subject.keywordPlus | INTERACTION NETWORKS | - |
| dc.subject.keywordPlus | BINDING-SITES | - |
| dc.subject.keywordPlus | HOT-SPOTS | - |
| dc.subject.keywordPlus | C-MYC | - |
| dc.subject.keywordAuthor | Azathioprine | - |
| dc.subject.keywordAuthor | Evolocumab | - |
| dc.subject.keywordAuthor | Fostemsavir | - |
| dc.subject.keywordAuthor | Sarilumab | - |
| dc.subject.keywordAuthor | Satralizumab | - |
| dc.subject.keywordAuthor | Siltuximab | - |
| dc.subject.keywordAuthor | Sotorasib | - |
| dc.subject.keywordAuthor | Terfenadine | - |
| dc.subject.keywordAuthor | Tocilizumab | - |
| dc.subject.keywordAuthor | Azathioprine | - |
| dc.subject.keywordAuthor | Cell Penetrating Peptide | - |
| dc.subject.keywordAuthor | Chemical Agent | - |
| dc.subject.keywordAuthor | Evolocumab | - |
| dc.subject.keywordAuthor | Fostemsavir | - |
| dc.subject.keywordAuthor | Immunoglobulin G4 | - |
| dc.subject.keywordAuthor | Interleukin 11 | - |
| dc.subject.keywordAuthor | Interleukin 27 | - |
| dc.subject.keywordAuthor | Interleukin 6 | - |
| dc.subject.keywordAuthor | Monoclonal Antibody | - |
| dc.subject.keywordAuthor | Myc Protein | - |
| dc.subject.keywordAuthor | Protein Protein Interaction Modulator | - |
| dc.subject.keywordAuthor | Sarilumab | - |
| dc.subject.keywordAuthor | Satralizumab | - |
| dc.subject.keywordAuthor | Siltuximab | - |
| dc.subject.keywordAuthor | Sotorasib | - |
| dc.subject.keywordAuthor | Terfenadine | - |
| dc.subject.keywordAuthor | Tocilizumab | - |
| dc.subject.keywordAuthor | Unclassified Drug | - |
| dc.subject.keywordAuthor | Allosterism | - |
| dc.subject.keywordAuthor | Amino Acid Sequence | - |
| dc.subject.keywordAuthor | Antiretroviral Therapy | - |
| dc.subject.keywordAuthor | Antiviral Activity | - |
| dc.subject.keywordAuthor | Apoptosis | - |
| dc.subject.keywordAuthor | Artificial Intelligence | - |
| dc.subject.keywordAuthor | Binding Affinity | - |
| dc.subject.keywordAuthor | Binding Site | - |
| dc.subject.keywordAuthor | Bioinformatics | - |
| dc.subject.keywordAuthor | Blood Brain Barrier | - |
| dc.subject.keywordAuthor | Cancer Growth | - |
| dc.subject.keywordAuthor | Carcinogenesis | - |
| dc.subject.keywordAuthor | Cardiotoxicity | - |
| dc.subject.keywordAuthor | Cd4+ T Lymphocyte | - |
| dc.subject.keywordAuthor | Cell Cycle Arrest | - |
| dc.subject.keywordAuthor | Cell Proliferation | - |
| dc.subject.keywordAuthor | Cell Survival | - |
| dc.subject.keywordAuthor | Cell Viability | - |
| dc.subject.keywordAuthor | Chemical Structure | - |
| dc.subject.keywordAuthor | Conformational Transition | - |
| dc.subject.keywordAuthor | Cryoelectron Microscopy | - |
| dc.subject.keywordAuthor | Cyclization | - |
| dc.subject.keywordAuthor | Cytokine Release | - |
| dc.subject.keywordAuthor | Cytotoxicity | - |
| dc.subject.keywordAuthor | Drug Design | - |
| dc.subject.keywordAuthor | Drug Development | - |
| dc.subject.keywordAuthor | Drug Formulation | - |
| dc.subject.keywordAuthor | Drug Metabolism | - |
| dc.subject.keywordAuthor | Ec50 | - |
| dc.subject.keywordAuthor | Epitope Mapping | - |
| dc.subject.keywordAuthor | Gene Expression | - |
| dc.subject.keywordAuthor | Genomic Instability | - |
| dc.subject.keywordAuthor | Heteronuclear Single Quantum Coherence | - |
| dc.subject.keywordAuthor | Highly Active Antiretroviral Therapy | - |
| dc.subject.keywordAuthor | Hospitalization | - |
| dc.subject.keywordAuthor | Human | - |
| dc.subject.keywordAuthor | Hydrogen Bond | - |
| dc.subject.keywordAuthor | Hydrolysis | - |
| dc.subject.keywordAuthor | Ic50 | - |
| dc.subject.keywordAuthor | Immune Response | - |
| dc.subject.keywordAuthor | Immunogenicity | - |
| dc.subject.keywordAuthor | Immunomodulation | - |
| dc.subject.keywordAuthor | Inflammation | - |
| dc.subject.keywordAuthor | Inflammatory Bowel Disease | - |
| dc.subject.keywordAuthor | Large Language Model | - |
| dc.subject.keywordAuthor | Machine Learning | - |
| dc.subject.keywordAuthor | Molecular Docking | - |
| dc.subject.keywordAuthor | Molecular Dynamics | - |
| dc.subject.keywordAuthor | Mouse | - |
| dc.subject.keywordAuthor | Multidrug Resistance | - |
| dc.subject.keywordAuthor | Mutagenicity | - |
| dc.subject.keywordAuthor | Nonhuman | - |
| dc.subject.keywordAuthor | Nuclear Magnetic Resonance Spectroscopy | - |
| dc.subject.keywordAuthor | Palmitoylation | - |
| dc.subject.keywordAuthor | Pharmacokinetic Parameters | - |
| dc.subject.keywordAuthor | Pharmacophore | - |
| dc.subject.keywordAuthor | Physical Chemistry | - |
| dc.subject.keywordAuthor | Protein Binding | - |
| dc.subject.keywordAuthor | Protein Protein Interaction | - |
| dc.subject.keywordAuthor | Protein Structure | - |
| dc.subject.keywordAuthor | Quantitative Structure Activity Relation | - |
| dc.subject.keywordAuthor | Review | - |
| dc.subject.keywordAuthor | Stoichiometry | - |
| dc.subject.keywordAuthor | Structural Bioinformatics | - |
| dc.subject.keywordAuthor | Structure Activity Relation | - |
| dc.subject.keywordAuthor | Support Vector Machine | - |
| dc.subject.keywordAuthor | Surface Plasmon Resonance | - |
| dc.subject.keywordAuthor | Ubiquitination | - |
| dc.subject.keywordAuthor | Virus Load | - |
| dc.subject.keywordAuthor | X Ray Crystallography | - |
| dc.subject.keywordAuthor | Drug Effect | - |
| dc.subject.keywordAuthor | Drug Therapy | - |
| dc.subject.keywordAuthor | Genetics | - |
| dc.subject.keywordAuthor | Metabolism | - |
| dc.subject.keywordAuthor | Neoplasm | - |
| dc.subject.keywordAuthor | Signal Transduction | - |
| dc.subject.keywordAuthor | Drug Discovery | - |
| dc.subject.keywordAuthor | Humans | - |
| dc.subject.keywordAuthor | Neoplasms | - |
| dc.subject.keywordAuthor | Protein Interaction Maps | - |
| dc.subject.keywordAuthor | Signal Transduction | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
